2025
Industrial Air Emissions and Breast Cancer Incidence in a United States-wide Prospective Cohort
Ish J, Madrigal J, Pearce J, Keil A, Fisher J, Jones R, Sandler D, White A. Industrial Air Emissions and Breast Cancer Incidence in a United States-wide Prospective Cohort. Epidemiology 2025, 36: 391-400. PMID: 39855262, DOI: 10.1097/ede.0000000000001837.Peer-Reviewed Original ResearchBreast cancer incidenceCancer incidenceBreast cancerIncidence of breast cancerEstimate adjusted hazard ratiosHazard ratioAssociated with breast cancerIncident breast cancerConfidence intervalsBreast cancer casesAdjusted hazard ratiosCox proportional hazards regressionProportional hazards regressionParticipating residentsCancer casesHazards regressionProspective cohortStudy enrollmentElevated associationIndustrial air emissionsIndustrial carcinogensCharacterized associationsBreastFollow-upPollutant mixtures
2023
Residential Proximity to Carcinogenic Industrial Air Emissions and Breast Cancer Incidence in a United States-Wide Prospective Cohort
Ish J, Madrigal J, Pearce J, Keil A, Fisher J, Jones R, White A. Residential Proximity to Carcinogenic Industrial Air Emissions and Breast Cancer Incidence in a United States-Wide Prospective Cohort. Cancer Epidemiology Biomarkers & Prevention 2023, 32: 865-865. DOI: 10.1158/1055-9965.epi-23-0376.Peer-Reviewed Original ResearchBreast cancer incidenceIncident breast cancerCancer incidenceHazard ratioParticipating residentsAssociated with breast cancer incidenceBreast cancerEstimate adjusted hazard ratiosAssociated with breast cancerConfidence intervalsBreast cancer casesIndustrial carcinogensAdjusted hazard ratiosCox proportional hazards regressionExposure-response functionsProportional hazards regressionBaseline residenceExposure prevalenceCancer casesResidential proximityHazards regressionProspective cohortIndustrial air emissionsParticipantsResidentsPredicting Breast Cancer Risk for Women Veterans of African Ancestry in the Million Veteran Program
Luoh S, Minnier J, Zhao H, Gao L. Predicting Breast Cancer Risk for Women Veterans of African Ancestry in the Million Veteran Program. Health Equity 2023, 7: 303-306. PMID: 37284538, PMCID: PMC10240329, DOI: 10.1089/heq.2023.0011.Peer-Reviewed Original ResearchBreast cancer riskBreast cancerMillion Veteran ProgramCancer riskPolygenic risk scoresWomen veteransHigher breast cancer riskRisk prediction instrumentsIncident breast cancerLow-risk womenBreast cancer preventionBreast cancer incidenceIndividual breast cancer riskBreast cancer mortalityPredicting Breast Cancer RiskBreast cancer screeningVeteran ProgramMajor health threatPrediction instrumentGenetic variantsEuropean ancestry womenProspective cohortRisk womenCancer mortalityCancer screening
2021
Polygenic Breast Cancer Risk for Women Veterans in the Million Veteran Program
Minnier J, Rajeevan N, Gao L, Park B, Pyarajan S, Spellman P, Haskell SG, Brandt CA, Luoh SW. Polygenic Breast Cancer Risk for Women Veterans in the Million Veteran Program. JCO Precision Oncology 2021, 5: 1178-1191. PMID: 34381935, PMCID: PMC8345920, DOI: 10.1200/po.20.00541.Peer-Reviewed Original ResearchConceptsBreast Cancer Risk Assessment ToolCancer Risk Assessment ToolIncident breast cancerAbsolute lifetime riskAA womenRisk assessment toolIncident casesLifetime riskBreast cancerMillion Veteran ProgramAccurate breast cancer risk assessmentProstate Cancer Cohort ConsortiumBreast cancer risk assessmentPrior BC diagnosisBreast cancer riskClinical risk modelVeteran ProgramRisk prediction modelCancer risk assessmentAssessment toolIncident BCAfrican ancestryHazard ratioProspective cohortMultiracial cohort
2018
Increased epigenetic age in normal breast tissue from luminal breast cancer patients
Hofstatter EW, Horvath S, Dalela D, Gupta P, Chagpar AB, Wali VB, Bossuyt V, Storniolo AM, Hatzis C, Patwardhan G, Von Wahlde MK, Butler M, Epstein L, Stavris K, Sturrock T, Au A, Kwei S, Pusztai L. Increased epigenetic age in normal breast tissue from luminal breast cancer patients. Clinical Epigenetics 2018, 10: 112. PMID: 30157950, PMCID: PMC6114717, DOI: 10.1186/s13148-018-0534-8.Peer-Reviewed Original ResearchConceptsNormal breast tissueBreast cancer patientsBreast cancerCancer patientsEpigenetic age accelerationBreast tissueAge accelerationLuminal breast cancer patientsNormal adjacent breast tissueNormal breast tissue samplesIncident breast cancerTissue samplesNon-tumor sitesBreast cancer riskImportant risk factorAdjacent breast tissueKomen Tissue BankChronological ageBreast cancer statusMalignant breast tissueNormal tissue samplesAge-related changesBreast tissue samplesBreast surgeryUnaffected womenProspective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers
Kim S, Huzarski T, Gronwald J, Singer C, Møller P, Lynch H, Armel S, Karlan B, Foulkes W, Neuhausen S, Senter L, Eisen A, Eng C, Panchal S, Pal T, Olopade O, Zakalik D, Lubinski J, Narod S, Kotsopoulos J, Ainsworth P, Bordeleau L, Tung N, Friedman E, Meschino W, Snyder C, Metcalfe K, Warner E, Rosen B, Demsky R, Weitzel J, Panabaker K, Couch F, Manoukian S, Pasini B, Daly M, Steele L, Saal H, Fallen T, Wood M, McKinnon W, Lemire E, Chudley A, Serfas K, Elser C, Vadaparampil S, Ginsburg O, Cullinane C, Blum J, Ross T, Mauer C, Kwong A, Cybulski C, McCuaig J, Rayson D, Isaacs C. Prospective evaluation of body size and breast cancer risk among BRCA1 and BRCA2 mutation carriers. International Journal Of Epidemiology 2018, 47: 987-997. PMID: 29547931, PMCID: PMC6005062, DOI: 10.1093/ije/dyy039.Peer-Reviewed Original ResearchBreast cancer riskCurrent body mass indexBRCA mutation carriersRisk of breast cancerBody mass indexPost-menopausal breast cancerCancer riskMutation carriersBreast cancerRisk of pre-menopausal breast cancerBiennial follow-up questionnairesHazard ratioIncident breast cancerEvaluation of body sizePre-menopausal breast cancerConfidence intervalsMeasures of adiposityBRCA2 mutation carriersFollow-up questionnaireWeight changeAssociated with riskCox proportional hazards modelsBaseline questionnaireProportional hazards modelFollow-up
2015
Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009
Dinan MA, Mi X, Reed SD, Lyman GH, Curtis LH. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009. JAMA Oncology 2015, 1: 1098. PMID: 26313372, DOI: 10.1001/jamaoncol.2015.2722.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic AgentsBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantChi-Square DistributionFemaleGene Expression ProfilingGenetic Predisposition to DiseaseGenetic TestingGuideline AdherenceHumansInsurance BenefitsMedicareMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPatient SelectionPhenotypePractice Guidelines as TopicPredictive Value of TestsRetrospective StudiesRisk AssessmentRisk FactorsSEER ProgramTime FactorsTreatment OutcomeUnited StatesConceptsReceipt of chemotherapyLower chemotherapy useHigh-risk diseasePatients 70 yearsChemotherapy useBreast cancerRecurrence scoreMedicare beneficiariesNational Comprehensive Cancer Network guidelinesEarly-stage breast cancerConsideration of chemotherapyLow-risk diseaseOverall chemotherapy useIncident breast cancerLow-risk patientsRetrospective cohort studyHigh-risk patientsPrespecified subgroup analysisUse of chemotherapyAdditional prognostic informationEnd Results (SEER) dataInvasive breast cancerRS assayNCCN riskAdjuvant chemotherapyInitial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009
Dinan MA, Mi X, Reed SD, Hirsch BR, Lyman GH, Curtis LH. Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009. JAMA Oncology 2015, 1: 158-166. PMID: 26181015, DOI: 10.1001/jamaoncol.2015.43.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsChemotherapy, AdjuvantChi-Square DistributionFemaleGene Expression ProfilingGenetic Predisposition to DiseaseGuideline AdherenceHealthcare DisparitiesHumansMedicareMultivariate AnalysisNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioPhenotypePractice Guidelines as TopicPractice Patterns, Physicians'Predictive Value of TestsRacial GroupsResidence CharacteristicsRetrospective StudiesRisk AssessmentRisk FactorsSEER ProgramTime FactorsTreatment OutcomeUnited StatesConceptsIntermediate-risk diseaseBreast cancerRecurrence scoreClinical practiceNode-negative breast cancerNational Comprehensive Cancer NetworkAdjuvant chemotherapy useIncident breast cancerComprehensive Cancer NetworkEnd Results (SEER) dataHigh-grade diseaseRetrospective observational studyRoutine clinical practiceTumor histologic characteristicsMedicare coverage decisionsAdjuvant chemotherapyChemotherapy useN1 diseaseMost patientsComorbid conditionsMultivariable analysisRS assayClinical variablesStudy criteriaBlack race
2010
Changes in the Use and Costs of Diagnostic Imaging Among Medicare Beneficiaries With Cancer, 1999-2006
Dinan MA, Curtis LH, Hammill BG, Patz EF, Abernethy AP, Shea AM, Schulman KA. Changes in the Use and Costs of Diagnostic Imaging Among Medicare Beneficiaries With Cancer, 1999-2006. JAMA 2010, 303: 1625-1631. PMID: 20424253, DOI: 10.1001/jama.2010.460.Peer-Reviewed Original ResearchConceptsNon-Hodgkin lymphomaLung cancerMedicare beneficiariesBreast cancerCancer typesColorectal cancerProstate cancerImaging costsPositron emission tomography scanIncident breast cancerYear of diagnosisEmission tomography scanBone density studiesMean total costMagnetic resonance imagingPositron emission tomographyBone scanTreatment patternsIncident casesCancer careHalf of beneficiariesTomography scanUS CentersMean annual increaseResonance imaging
2009
Energy Intake and Risk of Postmenopausal Breast Cancer: An Expanded Analysis in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort
Sue LY, Schairer C, Ma X, Williams C, Chang SC, Miller AB, McCarty CA, Willcox BJ, Ziegler RG. Energy Intake and Risk of Postmenopausal Breast Cancer: An Expanded Analysis in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO) Cohort. Cancer Epidemiology Biomarkers & Prevention 2009, 18: 2842-2850. PMID: 19843674, PMCID: PMC2783562, DOI: 10.1158/1055-9965.epi-09-0087.Peer-Reviewed Original ResearchConceptsFood frequency questionnaireOvarian Cancer Screening Trial (PLCO) cohortPostmenopausal breast cancerBreast cancerEnergy intakeTrial cohortDietary assessmentIncident breast cancerBody mass indexBreast cancer riskFirst food frequency questionnaireLower energy intakeModest positive associationMultivariate RRsFrequency questionnaireHighest quartileMass indexLowest quartilePhysical activitySimilar riskCancer riskHuman studiesAge 55CancerAnimal experiments
2008
Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal Women
Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL, Kaplan RC, Harris TG, Howard BV, Wylie-Rosett J, Burk RD, Strickler HD. Insulin, Insulin-Like Growth Factor-I, and Risk of Breast Cancer in Postmenopausal Women. Journal Of The National Cancer Institute 2008, 101: 48-60. PMID: 19116382, PMCID: PMC2639294, DOI: 10.1093/jnci/djn415.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedBiomarkers, TumorBlood GlucoseBody Mass IndexBreast NeoplasmsCase-Control StudiesEstradiolEstrogen Replacement TherapyFemaleHumansHyperinsulinismInsulinInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IMiddle AgedMultivariate AnalysisObesityOdds RatioPostmenopauseProportional Hazards ModelsProspective StudiesRisk AssessmentRisk FactorsStatistics, NonparametricConceptsInsulin-like growth factorLevels of insulinBreast cancerInsulin levelsRisk factorsPostmenopausal womenGrowth factorMultiple breast cancer risk factorsMultivariable Cox proportional hazards modelsWomen's Health Initiative Observational StudyBreast cancer case subjectsBreast cancer risk factorsCox proportional hazards modelHormone therapy useIncident breast cancerIndependent risk factorPostmenopausal breast cancerCancer risk factorsCase-cohort studyProportional hazards modelTotal IGFNondiabetic womenBaseline characteristicsFree IGFProspective cohort
1999
The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer.
Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE, Kelsey KT, Hunter DJ. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Research 1999, 59: 1015-20. PMID: 10070957.Peer-Reviewed Original ResearchConceptsHealth Study cohortBreast cancer riskBreast cancerHormone levelsA2 alleleCancer riskNurses' Health Study cohortStrong independent risk factorA2/A2 genotypeCYP17 A2 alleleElevated levelsAdvanced breast cancerIncident breast cancerIndependent risk factorPolycystic ovarian syndromeCertain steroid hormonesA1/A1 genotypeCase-control studyPlasma hormone levelsSteroid hormone levelsLater agePremenopausal womenCYP17 genotypeHormone replacementOvarian syndrome
1997
Glutathione S-transferase class mu deletion polymorphism and breast cancer: results from prevalent versus incident cases.
Kelsey KT, Hankinson SE, Colditz GA, Springer K, Garcia-Closas M, Spiegelman D, Manson JE, Garland M, Stampfer MJ, Willett WC, Speizer FE, Hunter DJ. Glutathione S-transferase class mu deletion polymorphism and breast cancer: results from prevalent versus incident cases. Cancer Epidemiology Biomarkers & Prevention 1997, 6: 511-5. PMID: 9232338.Peer-Reviewed Original ResearchConceptsBreast cancerGene deletion polymorphismCase seriesDeletion polymorphismHealth StudyNull genotypeGSTM1 deletionGlutathione S-transferase class muPrevalent breast cancerIncident breast cancerNurses' Health StudyGSTM1 gene deletion polymorphismBreast cancer riskDuration of survivalAge-matched controlsGSTM1 null genotypeBreast cancer prognosisMolecular epidemiologic studiesImproved survivalCigarette smokingIncident casesOdds ratioPrevalent casesEpidemiologic studiesCancer risk
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply